Grifols, S.A. GRFS
8.76 USD +0.07 (+0.81%)
At closeNov 10, 2026, 4:01 PM EST
8.76 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
8.60 Day range 8.78
6.96 52-week range 9.77
- YTD
- -6.31%
- 1 year
- +1.86%
News
seekingalpha.com Grifols: Plasma, Profits, And Recovery Gathering Momentum Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up…
benzinga.com Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase…
benzinga.com Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY https://www.grifols.com/en/view-news/-/news/grifols-increases-q1-2026-revenues-by-3-3-to-1-7billion-and-net-profit-21-9-to-73-million
benzinga.com Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market trading after beating analyst estimates.- benzinga.com 'Grifols' Canadian License Restricted After Plasma Donor Deaths' - Bloomberg https://www.bloomberg.com/news/articles/2026-04-02/grifols-canadian-license-restricted-after-plasma-donor-deaths
benzinga.com Grifols' Chronos-PD Study Demonstrates That Biological Changes In Individuals With Parkinson's Disease Occur More Than A Decade Before Clinical Diagnosis, With Potential Future Implications For Early Detection And Intervention Chronos‑PD shows that biological changes associated with Parkinson's disease (PD) can emerge up to 12 years before clinical diagnosis Uncovered reproducible early molecular signals and distinct…
benzinga.com Grifols Expects Reaching Free Cash Flow Pre-M&A Pre-Dividends Of €500M-575M; 2027 Milestones Unchanged; 2026 Adjusted EBITDA Margin Of Over 25% https://www.grifols.com/en/view-news/-/news/grifols-reports-revenues-of-eur-7524m-up-7-and-more-than-doubles-group-profit-to-eur-402m- benzinga.com CORRECTION: JP Morgan Maintains Neutral on Grifols, Maintains $10 Price Target (Price Target Updated - Rating Originally Published on 8th Dec) CORRECTION: JP Morgan analyst Richard Vosser maintains Grifols (NASDAQ:GRFS) with a Neutral and maintains $10 price target.
- benzinga.com JP Morgan Maintains Neutral on Grifols, Lowers Price Target to $10 JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and lowers the price target from $10.3 to $10.
benzinga.com Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday 
benzinga.com JP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.3 JP Morgan analyst James Gordon maintains Grifols (NASDAQ:GRFS) with a Neutral and raises the price target from $7.6 to $10.3.- benzinga.com Grifols Q1 Revenue €1.786 Billion; Adjusted EBITDA €400 Million; Q1 Net Income €60 Million; Confirms 2025 Guidance; Says On Track To Launch Fibrinogen In Europe In Q4'25 And In The U.S. In H1'26, Following FDA Approval; Expects To Share Greater Detail In 2025 Due To Impact Of Inflation Reduction Act On Its Financial Results https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D
benzinga.com Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket 
benzinga.com Grifols Chairman Thomas Glanzmann To Retire; To Be Succeeded Ann-Catherine Berner https://www.grifols.com/en/view-news/-/news/thomas-glanzmann-to-retire-as-grifols-chairman-and-will-be-succeeded-by-board-member-anne-catherine-berner- benzinga.com 'Grifols Shareholder Mason Capital Calls For Board Overhaul' - Bloomberg News https://www.bloomberg.com/news/articles/2024-12-02/grifols-shareholder-mason-capital-calls-for-board-to-be-replaced?sref=y3YMCJ4eMason Capital Management LLC's Kenneth M Garschina said he wants…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday? Grifols ends acquisition talks with Brookfield over valuation concerns, highlights strong revenue growth and financial stability in 2024.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Dell, HP, CrowdStrike, 3D Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- benzinga.com Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com 'Grifols Board Issues Unfavorable Opinion On Brookfield Offer; Brookfield And Grifols Family Have Been In Talks Since July; Investors Are Prepared To Push Back Against Low-Ball Offer' - Bloomberg News https://www.bloomberg.com/news/articles/2024-11-19/grifols-board-issues-unfavorable-opinion-on-brookfield-offer Grifols SA's board of directors said it won't recommend that shareholders accept…- benzinga.com Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com Reported Earlier, 'Banks To Pitch Roughly €11 Billion Buyout Debt For Grifols; Lenders Expected To Submit Best And Final Offers Next Week; Takeover Deal Likely To Rank Among Biggest In Europe This Year' - Bloomberg News https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifolsBanks are getting ready to submit final offers to Brookfield Asset Management for a…- benzinga.com Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management…
- benzinga.com GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen's…
- benzinga.com Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- benzinga.com Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?
- benzinga.com Zoom Video Posts Strong Q2 Results, Joins Peloton Interactive, Opera And Other Big Stocks Moving Higher On Thursday
- benzinga.com Brookfield Negotiates Over $10B In Debt Financing For Acquisition Of Spanish Pharma Giant Grifols Brookfield Asset Management is reportedly pursuing €9.5 billion in debt financing for a potential take-private deal for Grifols. The deal could lead to major financial restructuring, impacting…
- benzinga.com Grifols' GigaGen Receives FDA Clearance Of IND Application For Phase 1 Trial Of Recombinant Polyclonal For HBV Treatment, GIGA-2339 GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024Containing more…
- benzinga.com "Grifols' New Auditor Discovers Non-Cash Accounting Discrepancy Linked To China Stake; Spanish Company To Report Adjustment Related To China Stake; Discrepancy In Reserves Accounting Found By Auditor Deloitte" - Bloomberg News https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-stakeSpain's Grifols SA is set to report an unexpected accounting…
- benzinga.com Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Beleaguered Spanish Drug Firm Grifols Stock Jumps On Monday - Here's Why Grifols reveals Brookfield Capital's preliminary discussions with major shareholders about a potential joint bid to delist the company from Spanish stock exchanges and NASDAQ. An exclusivity…
- benzinga.com Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
benzinga.com Market-Moving News for July 8th GRFS: 31% | Brookfield Confirms It Held Exploratory Discussions With Certain Reference Shareholders Of Co In Relation To A Potential Joint Offer For Grifols' Shares To Delist Them SEDG: 7%- benzinga.com Brookfield Confirms It Held Exploratory Discussions With Certain Reference Shareholders Of Co In Relation To A Potential Joint Offer For Grifols' Shares To Delist Them In relation to certain rumors appearing in the media about a potential transaction involving Grifols, S.A. ("Grifols" or the "Company"), Brookfield confirms that it has held exploratory conversations…
- benzinga.com Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- benzinga.com Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as…
- benzinga.com Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- benzinga.com Grifols' Subsidiary Biotest Receives FDA Approval For Yimmugo, An Intravenous Immunoglobulin Therapeutic, To Treat Primary Immunodeficiencies, With US Launch Expected In Second Part Of 2024 With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing…
- benzinga.com Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease https://www.grifols.com/en/view-news/-/news/grifols-achieves-positive-results-from-phase-4-study-of-fanhdi-double-inactivated-human-anti-hemophilic-factor-in-patients-with-von-willebrand-disease
- benzinga.com CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday.
- benzinga.com Grifols Achieves Milestone In Transfusion Medicine With CE Mark For Procleix ArboPlex Assay Grifols' in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in…
- benzinga.com Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.
- benzinga.com Grifols Gets Downgraded: Fitch, S&P Flag Cash Flow Concerns At Pharma Company Fitch and S&P downgraded Grifols' ratings due to weak free cash flow and refinancing risks.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.